MX2014014840A - Peptido - mimeticos de la horquilla beta. - Google Patents

Peptido - mimeticos de la horquilla beta.

Info

Publication number
MX2014014840A
MX2014014840A MX2014014840A MX2014014840A MX2014014840A MX 2014014840 A MX2014014840 A MX 2014014840A MX 2014014840 A MX2014014840 A MX 2014014840A MX 2014014840 A MX2014014840 A MX 2014014840A MX 2014014840 A MX2014014840 A MX 2014014840A
Authority
MX
Mexico
Prior art keywords
cys11
xaa14
xaa15
xaa13
xaa6
Prior art date
Application number
MX2014014840A
Other languages
English (en)
Other versions
MX355396B (es
Inventor
Daniel Obrecht
Frank Otto Gombert
Johann Zimmermann
Alexander Lederer
Christian Oefner
Original Assignee
Polyphor Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polyphor Ag filed Critical Polyphor Ag
Publication of MX2014014840A publication Critical patent/MX2014014840A/es
Publication of MX355396B publication Critical patent/MX355396B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Los péptido-miméticos de la horquilla ß de la fórmula general ciclo (-Tyr1-His2-Xaa3-Cys4-Ser5-Xaa6-DPro7-Xaa8-Arg9-Tyr10-Cys11- Tyr12-Xaa13-Xaa14-Xaa15-Pro16-), el enlace disulfuro entre Cys4 y Cys11, y las sales aceptables farmacéuticamente del mismo, con Xaa3, Xaa6, Xaa8, Xaa14 y Xaa15 que son residuos de aminoácidos de ciertos tipos, los cuales se definen en la descripción y las reivindicaciones, tienen propiedades farmacológicas favorables y pueden ser usados para prevenir infecciones por VIH en individuos saludables, o para reparar y detener la progresión viral en pacientes infectados; o donde el cáncer está mediado o que resulta de la actividad del receptor CXCR4; o donde las enfermedades inmunológicas están mediadas o resultan de la actividad del receptor CXCR4; o para tratar la inmunosupresión; o durante las recolecciones por aféresis de las células madre de la sangre periférica y/o como agentes para inducir la movilización de las células madre para regular la reparación de los tejidos. Estos péptido-miméticos pueden ser fabricados mediante un proceso el cual se basa en una estrategia sintética mezclada, en fase sólida y en solución.
MX2014014840A 2012-06-06 2012-06-06 Peptido - mimeticos de la horquilla beta. MX355396B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/060766 WO2013182240A1 (en) 2012-06-06 2012-06-06 Beta-hairpin peptidomimetics

Publications (2)

Publication Number Publication Date
MX2014014840A true MX2014014840A (es) 2015-02-12
MX355396B MX355396B (es) 2018-04-18

Family

ID=46208596

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014840A MX355396B (es) 2012-06-06 2012-06-06 Peptido - mimeticos de la horquilla beta.

Country Status (13)

Country Link
US (2) US9617308B2 (es)
EP (1) EP2859012B1 (es)
JP (1) JP6047231B2 (es)
CN (1) CN104603145B (es)
AU (1) AU2012381808B2 (es)
CA (1) CA2875733C (es)
ES (1) ES2647076T3 (es)
HK (1) HK1207867A1 (es)
IL (1) IL235946B (es)
IN (1) IN2014KN02752A (es)
MX (1) MX355396B (es)
SG (1) SG11201407837WA (es)
WO (1) WO2013182240A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007348171B2 (en) 2007-02-28 2012-09-06 Polyphor Ltd. Template-fixed peptidomimetics
WO2013182240A1 (en) * 2012-06-06 2013-12-12 Polyphor Ag Beta-hairpin peptidomimetics
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
MX2017003201A (es) 2014-09-11 2017-05-23 Bristol Myers Squibb Co Inhibidores macrociclicos de las interacciones proteina/proteina de muerte programada 1 (pd-1)/pd-l1 y cd80(b7-1)/pd-l1.
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
SI3458111T1 (sl) 2016-05-19 2021-07-30 Bristol-Myers Squibb Company Imunomodulatorji prikazani s pet
WO2018048806A1 (en) * 2016-09-06 2018-03-15 Mainline Biosciences Cxcr4 antagonists and methods of use
CN110267971B (zh) 2016-11-07 2023-12-19 百时美施贵宝公司 免疫调节剂
KR20200020858A (ko) 2017-06-23 2020-02-26 브리스톨-마이어스 스큅 컴퍼니 Pd-1의 길항제로서 작용하는 면역조정제
CA3065086A1 (en) * 2017-09-05 2019-03-14 Mainline Biosciences High affinity cxcr4 selective binding conjugate and method for using the same
US11123437B2 (en) 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
US11492375B2 (en) 2017-10-03 2022-11-08 Bristol-Myers Squibb Company Cyclic peptide immunomodulators
JP2023516878A (ja) * 2020-01-26 2023-04-21 メインライン バイオサイエンシーズ（シャンハイ）シーオー．，エルティーディ． 同位体標識された選択的ｃｘｃｒ４結合性ペプチドコンジュゲート並びにその作製方法及び使用方法
CA3199171A1 (en) 2020-11-19 2022-05-27 Spexis Ag Pharmaceutical combinations comprising a peptide cxcr4 inhibitor and a taxane for treating cancer
WO2022184320A2 (en) 2021-03-03 2022-09-09 Spexis Ag Medical use of cyclic peptides
WO2023285681A1 (en) 2021-07-16 2023-01-19 Spexis Ag Pharmaceutical combinations for treating cancer
WO2023285677A1 (en) 2021-07-16 2023-01-19 Spexis Ag Pharmaceutical combinations for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212288A (en) * 1990-02-20 1993-05-18 Syntex (U.S.A.) Inc. Temporary minimal protection synthesis of serine-containing polypeptides
WO2004096839A1 (en) * 2003-05-02 2004-11-11 Polyphor Ag Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
JP5308829B2 (ja) * 2006-02-27 2013-10-09 テクニッシュ ユニべルシタット ミュンヘン 癌の画像化および処置
AU2007348171B2 (en) * 2007-02-28 2012-09-06 Polyphor Ltd. Template-fixed peptidomimetics
EP2427476B1 (en) * 2009-05-07 2018-08-08 Polyphor Ag Beta-hairpin peptidomimetics having cxcr4 antagonizing activity
US8716242B2 (en) * 2009-12-04 2014-05-06 Polyphor Ag β-hairpin peptidomimetics
BR112013031575B1 (pt) * 2011-06-07 2021-03-16 Polyphor Ag Composto peptídico ciclado de estrutura principal, composição farmacêutica, uso de um composto, e, processo para a manufatura de um composto
WO2013182240A1 (en) * 2012-06-06 2013-12-12 Polyphor Ag Beta-hairpin peptidomimetics

Also Published As

Publication number Publication date
US9617308B2 (en) 2017-04-11
ES2647076T3 (es) 2017-12-19
CA2875733A1 (en) 2013-12-12
NZ702470A (en) 2016-12-23
IL235946A0 (en) 2015-01-29
WO2013182240A1 (en) 2013-12-12
CN104603145A (zh) 2015-05-06
US20170165319A1 (en) 2017-06-15
JP2015521204A (ja) 2015-07-27
MX355396B (es) 2018-04-18
IN2014KN02752A (es) 2015-05-08
EP2859012A1 (en) 2015-04-15
JP6047231B2 (ja) 2016-12-21
US20150218219A1 (en) 2015-08-06
HK1207867A1 (en) 2016-02-12
IL235946B (en) 2019-06-30
SG11201407837WA (en) 2014-12-30
EP2859012B1 (en) 2017-08-09
AU2012381808B2 (en) 2017-04-27
CA2875733C (en) 2019-09-10
CN104603145B (zh) 2018-05-18
US10363284B2 (en) 2019-07-30
AU2012381808A1 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
MX355396B (es) Peptido - mimeticos de la horquilla beta.
MX343205B (es) Peptidomiméticos de horquilla beta como antagonistas de cxc4.
MX2009008843A (es) Peptidomimeticos fijados a un patron.
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
WO2013079701A3 (en) Expression of mirnas in placental tissue
PH12014502041A1 (en) Heterocyclyl compounds as mek inhibitors
EA201890236A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
MX363050B (es) Composición inmunogénica para modulación del sistema inmune y su uso, metodo de tratamiento y prevención de enfermedades, método para inducir la regeneración celular y procedimiento para la reconducción de la respuesta inmune.
GB2546224A (en) Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous physiological fluid
WO2013106385A3 (en) System and methods for determining tissue elasticity
GR1007832B (el) Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
BR112012028437A2 (pt) solução oftálmica, e, método para tratar glaucoma ou hipertensão ocular
ES2421717T3 (es) Fosfatasa alcalina para aumentar la actividad del sistema inmune en un mamífero con riesgo de enfermedades inflamatorias
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
EA201790563A1 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
MX2015007402A (es) Fusion de hormona de crecimiento humano y albumina, formulacion y usos de los mismos.
MX2016008468A (es) Peptidomimeticos de horquilla beta como inhibidores de elastasa selectivos.
WO2012177660A3 (en) Leukotoxin e/d as a new anti-inflammatory agent and microbicide
EA201591095A1 (ru) Белок slurp-1 для применения в лечении глазных болезней
NZ702666A (en) A method of weight reduction
UA107155C2 (uk) Стабільна композиція для лікування герпесвірусних інфекцій
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
CN205357113U (zh) 割草机刀架盘
RU2010127731A (ru) Способ лечения гнойно-воспалительных осложнений у онкоурологических больных
UA130761U (uk) Спосіб лікування ендометриту, індукованого генітальною герпесвірусною інфекцією

Legal Events

Date Code Title Description
FG Grant or registration